A study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests that injecting engineered dendritic cells directly into cancerous lung tumors can help promote a stronger immune response, causing more ...
Mar 26, 2024
0
0
Mayo Clinic researchers have used a new approach to chemotherapy to more than double the typical survival rate for patients with stomach cancer and peritoneal metastasis, which is cancer that has spread to the lining of the ...
Apr 23, 2024
0
1
Retinoblastoma is a rare pediatric cancer, with approximately 250–300 new cases per year in the United States and 8,000 worldwide. The cancer grows within the retina, a thin layer of cells at the back of the eye, and is ...
Apr 22, 2024
0
0
Non-small cell lung cancer accounts for nearly 85% of all lung cancer cases. Targeted immunotherapy is a common treatment, but it does not work for everyone. However, a new Moffitt Cancer Center study published in the journal ...
Apr 18, 2024
0
4
For the first time in fifty years, results from a Phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.
Apr 17, 2024
0
1
Women with triple-negative breast cancer, and high levels of immune cells in the tumors, have a lower relapse risk after surgery, even without chemotherapy, according to a recent study published in JAMA.
Apr 17, 2024
0
5
Through millions of years of evolutionary refinement, the human body has developed a sophisticated surveillance mechanism—the immune system. This intricate network is constantly scanning the body for invaders such as bacteria, ...
Apr 17, 2024
0
1
A new study examines the development of two machine learning models to classify the immunophenotype of a cancer specimen.
Apr 16, 2024
0
0
Transferring fecal microbiota from healthy donors to the intestines of chronically ill people has beneficial effects on these recipients' gut bacteria, also in the longer term. This is the conclusion of research by the Leiden ...
Apr 16, 2024
0
0
A specific genetic alteration, known as an ALK fusion, drives non-small cell lung cancer in some patients. This abnormality leads to excessive activity of the ALK protein, a key cancer promoter. These tumors can be treated ...
Apr 16, 2024
0
26
